このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

急性脊髄損傷における経皮的脛骨神経刺激 (TASCI)

2026年11月2日 更新者:University of Zurich

神経原性排尿筋過活動を予防するための急性脊髄損傷患者における経皮的脛骨神経刺激:全国的な無作為化偽対照二重盲検臨床試験

Most patients with spinal cord injury (SCI) develop neurogenic lower urinary tract dysfunction (NLUTD), one of the most devastating sequelae of SCI which ultimately can lead to renal failure. We urgently need an intervention that prevents NLUTD before irreversible damage occurs. Neuromodulation procedures are a promising avenue so that we investigate the effect of transcutaneous tibial nerve stimulation (TTNS) in patients with acute SCI.

This nationwide randomized, sham-controlled, double-blind multicentre clinical trial includes all SCI centres in Switzerland (Basel, Nottwil, Sion, Zürich). Patients are randomly assigned to VERUM TTNS (active stimulation, n=57) and SHAM stimulation (n=57) groups in a 1:1 allocation using computer-generated permuted block randomisation lists stratified on study centre and lower extremity motor score. Daily 30-minute sessions are performed five times a week during an intervention period of 6-9 weeks. The primary outcome of this study is the success of TTNS to prevent neurogenic DO jeopardizing the upper urinary tract, assessed by urodynamics at 1 year after SCI or any earlier time point if DO treatment is necessary (study end). Secondary outcome measures are bladder diary parameters, clinical symptom scores assessed by standardized and validated questionnaires. Furthermore, neurophysiological and neuroimaging outcome measures are assessed as well as, biochemical and molecular changes. Tertiary outcome measure is the safety of TTNS.

Before the actual start of the TASCI RCT, start-up activities will include a piloting phase on groups of healthy volunteers and patients. The goal during this phase is to evaluate the feasibility of the experimental setup, in particular for the TTNS and SHAM intervention, but also to test the setup of the different pre and post assessments (e.g. neurophysiology and neuroimaging tests). Groups of up to 15 participants each will be enrolled in a few consecutive pilot studies allowing for fine tuning and small adaptations in between, if appropriate.

調査の概要

状態

募集

条件

介入・治療

研究の種類

介入

入学 (推定)

114

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究連絡先のバックアップ

研究場所

      • Basel、スイス
        • 募集
        • REHAB Basel
        • コンタクト:
        • 主任研究者:
          • Sandra Möhr, pract. med.
      • Nottwil、スイス
        • 募集
        • Swiss Paraplegic Centre
        • コンタクト:
        • 主任研究者:
          • Jürgen Pannek, Prof. Dr. med.
      • Sion、スイス
        • 募集
        • Spinal Cord Injury Department, Clinique romande de réadaption
        • コンタクト:
        • 主任研究者:
          • Xavier Jordan, Dr. med.
    • Canton of Zurich
      • Zurich、Canton of Zurich、スイス、8008
        • 募集
        • Department of Neuro-Urology, Spinal Cord Injury Centre & Research, Balgrist University Hospital
        • コンタクト:
        • 主任研究者:
          • Thomas M Kessler, Prof. Dr. med.

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Age >18 years

  • Patients with acute SCI (traumatic SCI and sudden onset (<7 days) non-traumatic SCI) within 40 days after injury

  • Patients with acute SCI at cervical or thoracic level

  • Willing to take part and follow the requirements of the TASCI protocol (up to one year after SCI)

    • no percutaneous tibial nerve stimulation (PTNS)
    • no functional electrical stimulation (FES), apart from upper limb FES
    • no electrical muscle stimulation (EMS)
  • Informed Consent

Exclusion Criteria:

  • Contraindications to the investigational product
  • DO with contractions greater than 40 cmH2O at a bladder filling volume of less than 500mL at baseline visit
  • Treatment with antimuscarinics or with mirabegron
  • Known or suspected non-adherence, drug or alcohol abuse
  • Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant
  • Participation in another study with investigational drug or product within the 30 days preceding and during the present study
  • Neuromodulation treatment for urological or bowel indication in the last six months or ongoing
  • Botulinum toxin injections in the detrusor and/or urethral sphincter in the last six months
  • Bilaterally absent tibial nerve compound muscle action potential (cMAP, amplitude < 1mV)
  • Women who are pregnant or breast feeding
  • Intention to become pregnant during the course of the study
  • Individuals especially in need of protection (according to Research with Human Subjects published by the Swiss Academy of Medical Sciences [www.samw.ch/en/News/News.html])
  • Enrolment of the investigator, his/her family members, employees and other dependent persons
  • Pre-existing or concomitant medical condition apart from SCI that might pose a safety issue or would interfere with interpretation of study results or study conduct (e.g. Parkinson's disease, neurodegenerative disorders including multiple sclerosis and amyotrophic lateral sclerosis, urological malignancies)

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:防止
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:トリプル

武器と介入

参加者グループ / アーム
介入・治療
実験的:VERUM経皮脛骨神経刺激(TTNS)
  • Daily 30-minute TTNS intervention is performed 5 days a week during a treatment period of 6-9 weeks, until 3-month post assessments
  • During a preparation phase of several minutes, sensory and motor thresholds are assessed and stimulation intensities are adjusted for the following 30-minute treatment phase
偽コンパレータ:SHAM経皮脛骨神経刺激(TTNS)
  • Daily 30-minute SHAM intervention is performed 5 days a week during a treatment period of 6-9 weeks, until 3-month post assessments
  • During a preparation phase of several minutes, sensory and motor thresholds are assessed and stimulation intensities are adjusted for the following 30-minute treatment phase

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
The occurrence of neurogenic DO jeopardizing the upper urinary tract
時間枠:up to 12 months after SCI

Defined as composite measure: Urodynamic assessment establishing DO amplitude ≥40 cmH2O; or else initiation of DO treatment (with antimuscarinics and/or intradetrusor onabotulinumtoxinA injections)

up to 12 months after SCI

二次結果の測定

結果測定
メジャーの説明
時間枠
尿力学中の膀胱コンプライアンス [mL/cmH2O] の変化と臨床転帰との関係
時間枠:ベースライン; SCIの3か月後。 SCIの6か月後。 SCI/試験終了後12ヶ月
ベースライン; SCIの3か月後。 SCIの6か月後。 SCI/試験終了後12ヶ月
尿力学によって評価される最大流量 [mL/s] の変化と臨床転帰との関係
時間枠:ベースライン; SCIの3か月後。 SCIの6か月後。 SCI/試験終了後12ヶ月
ベースライン; SCIの3か月後。 SCIの6か月後。 SCI/試験終了後12ヶ月
尿力学中のビデオ撮影によって評価される膀胱尿管腎逆流(VUR)の変化と臨床転帰との関係
時間枠:ベースライン; SCIの3か月後。 SCIの6か月後。 SCI/試験終了後12ヶ月
ベースライン; SCIの3か月後。 SCIの6か月後。 SCI/試験終了後12ヶ月
尿力学中の筋電図(EMG)によって評価される骨盤底活動の変化と臨床転帰との関係
時間枠:ベースライン; SCIの3か月後。 SCIの6か月後。 SCI/試験終了後12ヶ月
ベースライン; SCIの3か月後。 SCIの6か月後。 SCI/試験終了後12ヶ月
国際脊髄学会(ISCoS)の女性/男性性機能データセットの変化と臨床転帰との関係
時間枠:ベースライン; SCIの3か月後。 SCIの6か月後。 SCI/試験終了後12ヶ月
ベースライン; SCIの3か月後。 SCIの6か月後。 SCI/試験終了後12ヶ月
肛門直腸内圧測定およびバロスタット評価中の直腸コンプライアンス [mL/cmH2O] の変化とそれらの臨床転帰との関係
時間枠:ベースライン; SCIの3か月後。 SCIの6か月後。 SCI/試験終了後12ヶ月
ベースライン; SCIの3か月後。 SCIの6か月後。 SCI/試験終了後12ヶ月
誘発電位(EP)の神経生理学的測定および神経伝導測定の変化とそれらの臨床転帰との関係
時間枠:ベースライン; SCIの3か月後。 SCIの6か月後。 SCI/試験終了後12ヶ月
ベースライン; SCIの3か月後。 SCIの6か月後。 SCI/試験終了後12ヶ月
下部尿路 (LUT) 神経生理学の変化: 現在の知覚閾値 (CPT) および LUT 感覚誘発電位 (LUTSEP) と臨床転帰との関係
時間枠:ベースライン; SCIの3か月後。 SCIの6か月後。 SCI/試験終了後12ヶ月
ベースライン; SCIの3か月後。 SCIの6か月後。 SCI/試験終了後12ヶ月
膀胱組織、血液、尿中の炎症マーカーの変化と臨床転帰との関係
時間枠:ベースライン; SCIの3か月後。 SCIの6か月後。 SCI/試験終了後12ヶ月
ベースライン; SCIの3か月後。 SCIの6か月後。 SCI/試験終了後12ヶ月
膀胱組織の変化と臨床転帰との関係
時間枠:ベースライン; SCIの3か月後。 SCIの6か月後。 SCI/試験終了後12ヶ月
ベースライン; SCIの3か月後。 SCIの6か月後。 SCI/試験終了後12ヶ月
Volumetric changes during urodynamics and their relation to clinical outcomes
時間枠:Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

Cystometric capacity [mL], volume at first DO [mL], voided volume [mL] and post void residual [mL] as assessed by urodynamic measurement

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Pressure changes during urodynamics and their relation to clinical outcomes
時間枠:Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

Maximum DO amplitude [cmH2O], detrusor leak-point pressure [cmH2O], maximum detrusor pressure [cmH2O] during storage phase, maximum detrusor pressure [cmH2O] during voiding phase, detrusor pressure at maximum flow rate [cmH2O] as assessed by urodynamic measurement

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in bladder storage and voiding parameters and their relation to clinical outcomes
時間枠:Baseline; once every 2 weeks during the TTNS intervention period; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

Assessed by a bladder diary

Baseline; once every 2 weeks during the TTNS intervention period; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in bowel diary parameters and their relation to clinical outcomes
時間枠:Baseline; once every 2 weeks during the TTNS intervention period; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

Assessed by a bowel diary

Baseline; once every 2 weeks during the TTNS intervention period; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in International Prostate Symptom (IPSS) questionnaire and their relation to clinical outcomes
時間枠:Baseline; once per week during the TTNS intervention period; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

The IPSS ("International Prostate Symptom Questionnaire") score is based on questions concerning urinary symptoms and quality of life (QoL). It consists of 8 items covering 7 urinary symptoms related dimensions (subscales) and 1 additional item assessing quality of life. Each item is rated on a 6-point scale (0=not at all; 5=almost always). The lowest possible score in the total IPSS score is 0 (asymptomatic); the highest possible score is 35 (symptomatic). The QoL index is rated on a 7-point scale, with 0 indicating "delighted" and 6 "terrible."

Baseline; once per week during the TTNS intervention period; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in urinary symptoms as assessed by the Urinary Symptom Profile (USP) questionnaire and their relation to clinical outcomes
時間枠:Baseline; once per week during the TTNS intervention period; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

The USP ("Urinary Symptom Profile") score is based on questions concerning urinary symptoms and their severity in males and females. It consists of 13 items covering 3 dimensions (subscales) with 7 overactive bladder (OAB), 3 stress urinary incontinence (SUI), and 3 low stream (LS) related items. Each item is rated on a 4-point scale. The lowest score is 0 (asymptomatic); the highest score is 3 (symptomatic).

Baseline; once per week during the TTNS intervention period; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in Qualiveen questionnaire scores and their relation to clinical outcomes
時間枠:Baseline; once per week during the TTNS intervention period; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

Qualiveen-30 assesses the Specific Impact of Urinary Problems (SIUP) on Quality of Life. It consists of 30 items covering 4 domains, namely inconvenience (9 questions), restrictions (8 questions), fears (8 questions), and impact on daily life (5 questions). Each item is rated on a 5-point ordinal scale (0=asymptomatic; 4=symptomatic). The index of the SIUP on Quality of Life is the mean of the four individual scores. The lowest possible overall score in the Qualiveen-30 is 0 (Urinary problems have no specific impact on QoL); the highest possible score is 30 (Urinary problems have a huge specific impact on QoL).

Baseline; once per week during the TTNS intervention period; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in Female Sexual Function Index (FSFI) and their relation to clinical outcomes
時間枠:Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

The FSFI ("Female Sexual Function Index") is based on questions concerning female sexual functions. It consists of 19 items covering 6 domains, namely sexual desire, arousal (both subjective and physiologic), lubrication, orgasm, satisfaction, and pain. The lowest possible score in the total FSFI is 2 (asymptomatic); the highest possible score is 36 (symptomatic).

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in International Index of Erectile Function (IIEF) and their relation to clinical outcomes
時間枠:Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

The IIEF ("International Index of Erectile Function") is based on questions concerning erectile dysfunction. It consists of 15 items covering 5 domains, namely erectile functioning, orgasmic functioning, sexual desire, and intercourse satisfaction along with a fifth component which encompasses the concept of overall sexual satisfaction. While items 1-10 are rated on a 6-point Likert-type scale from 0 to 5, items 11-15 are rated on a 5-point Likert-type scale from 1 to 5. Higher scores are reflecting less dysfunction. Domain scores are computed by summing the sores for individual items in each domain.

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in Neurogenic Bowel Dysfunction (NBD) score and their relation to clinical outcomes
時間枠:Baseline; once per week during the TTNS intervention period; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

The NBD ("Neurogenic Bowel Dysfunction") score is based on questions concerning constipation and fecal incontinence and was developed for and validated in the spinal cord injury population. It consists of 10 items. The lowest possible score in the total NBD is 0 (asymptomatic); the highest possible score is 47 (symptomatic). The interpretation of the total NBD score is very minor NBD (0-6), minor NBD (7-9), moderate NBD (10-13), and severe NBD (≥14).The NBD score is assessed by using the international spinal cord injury (ISCoS) bowel function basic data set.

Baseline; once per week during the TTNS intervention period; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Volumetric changes during rectal sensitivity testing and barostat assessment and their relation to clinical outcomes
時間枠:Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

Initial sensation [mL], volume at urge to defecate [mL], maximum tolerated volume [mL] as assessed by rectal sensitivity testing; rectal capacity [mL] assessed by barostat assessment

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Pressure changes during anorectal manometry and barostat assessment and their relation to clinical outcomes
時間枠:Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

Basal internal anal sphincter pressure [mmHg], squeeze external anal sphincter pressure [mmHg], relaxation internal anal sphincter pressure during defecation [%, mmHg], intraabdominal pressure during defecation [mmHg]

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in defecatory disorder [Rao's classification] identified during anorectal manometry and their relation to clinical outcomes
時間枠:Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

Anorectal manometry is the preferable test for defecatory disorder. Rao's classification describes the four types of manometric patterns (I-IV) that are identified through manometric assessments

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) protocol
時間枠:Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) assessment to quantify the severity of the spinal cord injury

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in Lower Extremities Motor Scale (LEMS) from International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) protocol
時間枠:Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

LEMS is based on assessments of ISNCSCI and composed from the sum of muscle function grading of the five key muscles of the lower limbs. It consists of a 6-point scale (0=no; 5=normal activity) for each muscle and body site. The lowest possible score in the total LEMS score for one body site is 0 (symptomatic); the highest possible score is 50 (asymptomatic).

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in Upper Extremities Motor Scale (UEMS) from International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) protocol
時間枠:Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

UEMS is based on assessments of ISNCSCI and composed from the sum of muscle function grading of the five key muscles of the upper limbs. It consists of a 6-point scale (0=no; 5=normal activity) for each muscle and body site. The lowest possible score in the total LEMS score for one body site is 0 (symptomatic); the highest possible score is 50 (asymptomatic).

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in Spinal Cord Independence Measure III (SCIM-III) and their relation to clinical outcomes
時間枠:Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

The SCIM-III ("Spinal Cord Independence Measure III") score is based on questions concerning independence of persons with a spinal cord injured. It consists of 19 items covering 3 domains, self-care, respiration and sphincter management, and mobility. The self-care subscale ranges from 0 to 20. The respiration and sphincter management subscale ranges from 0 to 40. The mobility subscale ranges from 0 to 40. Total score ranges from 0 (symptomatic) to 100 (asymptomatic). Higher scores reflect higher levels of independence.

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in spasticity in the knee and elbow flexors and extensors from the Modified Ashworth Scale (MAS) assessment and their relation to clinical outcomes
時間枠:Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

The MAS is a 5-point nominal scale that uses subjective clinical assessments of muscle tone ranging from 0 - 'No increases in tone' to 4 - 'Limb rigid in flexion or extension'. A grade of (1+) indicates resistance in the movement.

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in spasticity in daily life as assessed by the Spinal Cord Injury Spasticity Evaluation Tool (SCI-SET) questionnaire and their relation to clinical outcomes
時間枠:Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

The SCI-SET ("Spinal Cord Injury Spasticity Evaluation Tool ") score is based on questions concerning the positive and negative effects of spasticity on different areas of daily life. Each of the 35 items are rated on a 7-point scale (-3=extremely problematic; 0=no effect; 3=extremely helpful). Calculations include counts and sum scores of areas of daily life where spasticity is problematic (count range: 0 to 35, sum score range: 35 to 0) or helpful (counts range: 0 to 35, sum score range: 0 to +35) as well as a mean score of all applicable items (range: -3 to +3)

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in frequency power of surface electromyography (EMG) and electroencephalography (EEG) and their relation to clinical outcomes
時間枠:Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

Fast Fourier Transformation analysis for delta, theta, alpha, beta, and gamma band power as assessed via EEG of the cortex and EMG of the muscle

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in EMG and EEG coherence measures and their relation to clinical outcomes
時間枠:Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

Coherence for EEG and EMG signals computed as cortico-muscular, inter- and intra-muscular coherence for typical EEG/EMG frequency bands (delta, theta, alpha, beta, and gamma).

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in white and gray matter area in the lumbosacral enlargement (LSE) and their relation to clinical outcomes
時間枠:Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

White and gray matter areas are obtained by segmenting the T2*-weighted MRI images for white and gray matter at the level of LSE

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in white and gray matter area in upper cervical cord (at C2/C3) and their relation to clinical outcomes
時間枠:Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

Obtained by segmenting the T2*-weighted MRI images for white and gray matter at the vertebral level C2/C3.

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in white and gray matter volume of the conus medullaris (CM) and their relation to clinical outcomes
時間枠:Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

White and gray matter volume are obtained by segmenting the T2*-weighted MRI images for white and gray matter in the CM

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in gray and white matter volume in the brain and their relation to clinical outcomes
時間枠:Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

Gray and white matter volume in the brain are computed by feeding the whole-brain T1-weighted MRI images into a voxel-based morphometry algorithm. Changes in the gray and white matter volume will be evaluated in urologically relevant brain areas.

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in fractional anisotropy (FA) in the brain and spinal cord and their relation to clinical outcomes
時間枠:Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

FA is a common dimensionless measure used in Diffusion Tensor Imaging (DTI) studies and ranges from 0, isotropic movement of water molecules (e.g., cerebrospinal fluid), to 1, fully anisotropic movement of water molecules (e.g., fiber bundles).

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in diffusivity in the brain and spinal cord and their relation to clinical outcomes
時間枠:Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

Mean, axial, and radial diffusivity (MD, AD, RD) are common measures used in DTI studies providing information about the integrity of the underlying tissue.

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in brain and spinal cord tissue microstructure and their relation to clinical outcomes
時間枠:Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

Quantitative tissue parameters assessed using MRI Multi-Parameter Mapping.

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Expression profile of microRNA (miRNA) in urine and blood as well as their relation to clinical outcomes
時間枠:Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

MicroRNA (miRNA) sequencing is used to identify regulated miRNAs specific to TTNS intervention in urine and blood.

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in levels of neurotransmitters (neurotrophins) in blood, and urine, as well as their relation to clinical outcomes
時間枠:Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

Analysis will be performed using ELISA to detect molecules likely to be involved in the underlying molecular mechanisms of neuromodulation.

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end
Changes in the composition of urinary and stool microbiome and their relation to clinical outcomes
時間枠:Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

Gut and bladder microbial patterns are determined from stool and urine samples

Baseline; 3 months after SCI; 6 months after SCI; 12 months after SCI / study end

その他の成果指標

結果測定
メジャーの説明
時間枠
Incidence of side effects as well as number and intensity/severity (mild/moderate/severe) of adverse events (AEs) and serious adverse events (SAEs) for the following categories:
時間枠:During complete study period, up to 12 months
  • infection - Urinary Tract Infection (UTI)
  • infection - other than UTI
  • skin irritation at the electrode site
  • irritation-related symptoms (e.g. dysuria, hematuria) immediately following a LUT intervention
  • neuro-urological deterioration
  • pressure ulcer
  • neurological deterioration
  • increase in pain
  • increase in spasticity
  • deep vein thrombosis / pulmonary embolism
  • autonomic dysreflexia
  • transfer/admittance to an acute care facility
During complete study period, up to 12 months

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

協力者

捜査官

  • スタディチェア:Thomas M. Kessler, Prof. Dr. med.、University of Zurich
  • 主任研究者:Thomas M. Kessler, Prof. Dr. med.、Balgrist University Hospital
  • 主任研究者:Armin Curt, Prof. Dr. med.、Balgrist University Hospital
  • 主任研究者:Jürgen Pannek, Prof. Dr. med.、Swiss Paraplegic Centre
  • 主任研究者:Martin Brinkhof, Dr.、Swiss Paraplegic Research, Nottwil

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

一般刊行物

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2019年6月19日

一次修了 (推定)

2028年9月30日

研究の完了 (推定)

2028年9月30日

試験登録日

最初に提出

2019年3月26日

QC基準を満たした最初の提出物

2019年5月23日

最初の投稿 (実際)

2019年5月29日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月5日

QC基準を満たした最後の更新が送信されました

2026年11月2日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • 2019-00074
  • 2019 (米国 NIH グラント/契約)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

All individual participant data (IPD) and data dictionaries that underlie results in a publication are to be uploaded to a public data registry in cases where this can be done without compromising patient privacy. Given the small size of the dataset and that spinal cord injury (SCI) is a rare condition, to ensure identity protection any publicly available dataset(s) will be modified to reduce the number of indirect identifier variables, e.g. continuous variables such as age will be grouped, categorical or binary variables with small group numbers such as study centre will not be provided. When data sets cannot be sufficiently de-identified to be made publicly available, they will be made available upon reasonable request. Data judged to be confidential to participants or the participating study centers will not be released, but efforts will be made to provide scientifically meaningful equivalent information.

IPD 共有時間枠

Post-publication data packages, containing the analysis data set presented in scientific reports will be available starting 6 months after the publication date. Data that are not being prepared for publication will be available to secondary users starting 4 years after study completion or discontinuation. All data will be kept for at least 10 years after study completion or discontinuation.

IPD 共有アクセス基準

Requests for data access will be reviewed by the TASCI steering committee, which includes the four project PIs and representatives from each of the participating study centers. The steering committee will request a project plan, including at a minimum an abstract and a list of author names and roles, from the leaders of all projects wishing to use TASCI study data. Project plans will be evaluated on the basis of scientific validity, and also on whether they include adequate measures to protect patient privacy. Secondary users will be asked to sign a data use agreement.

IPD 共有サポート情報タイプ

  • ANALYTIC_CODE

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。